Shafaq Zia is a science journalist and a graduate student in the Graduate Program in Science Writing at the Massachusetts Institute of Technology. Previously, she was a reporting intern at STAT, covering the COVID-19 pandemic and the latest research in health technology.
Shafaq Zia
From this contributor
Spotted around the web: COVID-19 during pregnancy, sleep problems, eugenics
Here is a roundup of news and research for the week of 6 June.
Spotted around the web: COVID-19 during pregnancy, sleep problems, eugenics
By
Jill Adams, Angie Voyles Askham, Peter Hess, Shafaq Zia
10 June 2022 | 3 min read
New resource tracks genetic variations in Han Chinese populations
An online database called NyuWa catalogs genetic variations among nearly 3,000 individuals and provides a comprehensive reference genome for the Han people.
New resource tracks genetic variations in Han Chinese populations
By
Shafaq Zia
9 December 2021 | 3 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read